Axovant Sciences (AXON) Shares Resume Trading, Look to Bounce Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Stocks and yen struggle as tech troubles weigh
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen hits fresh 34-year lows against dollar ahead of BOJ meeting
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Axovant Sciences (AXON) says Lunbeck study failure was expected - Bloomberg
September 22, 2016 3:40 PM EDTAxovant Sciences (NYSE: AXON) says Lunbeck study failure in Alzheimer's disease was expected, according to Bloomberg, citing a company email.
Axovant noted that weak efficacy in phase 3 wasn't surprising.
... MoreBaird Defends Axovant Sciences (AXON) After Lundbeck; No Change to Outlook
September 22, 2016 1:35 PM EDTBaird analyst Brian Skorney came out to defend Axovant Sciences (NYSE: AXON), which is getting slammed on rival Lundbeck top-line results.
Skorney commented, "Lundbeck reported failure of Phase 3 STARSHINE trial of idolapirdine, a 5-HT6 antagonist, sending shockwaves through Axovant's stock. However, we... More
Axovant Sciences (AXON) Sinks as Lundbeck 5-HT6 antagonist Fails
September 22, 2016 12:11 PM EDTAxovant Sciences (NYSE: AXON) weakens on news Lundbeck 5-HT6 antagonist fails in Alzheimer's Phase III. Adam Feuerstein notes on Twitter that AXON also has a 5-HT6 antagonist.
Watch $AXON for reaction. Also developing a 5-HT6 antagonist in Alzheimers. https://t.co/j0sd2NAZBz
— Adam Feuerstein (@adamfeuerstein) September 22, 2016... More
Axovant Sciences (AXON) trading paused for volatility
September 22, 2016 12:10 PM EDTAxovant Sciences (NYSE: AXON) trading paused for volatility.
... More
